Vidac Pharma - Publications

News & Events

ARTICLES

A Hexokinase 2 Modulator for Field-Directed Treatment of Experimental Actinic Keratoses.

Behar V., Pahima H., Kozminsky-Atias A., Arbel N., Loeb E., Herzberg M. and Becker O. M., Journal of Investigative Dermatology (2018), 138(12):2635-2643.

POSTERS
	SITC 2018: Modulating Hexokinase 2 (HK2) as a Novel Approach for Simultaneous Targeting of the Tumor and Its Immunosuppressive Microenvironment
	Fall Clinical Dermatology Conference ® 2018 A Novel Well-Tolerated Treatment for Actinic Keratosis.
	AACR 2018: Activating the NLRP3 Inflammasome in Macrophages and Triggering Apoptosis in Cancer Cells via HK2/VDAC Modulator.

LiveSites | Login

To Top